CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
EV to Sales: Discounted Valuation
Trending higher, below historical average, structural decline.
Left:
||||
Enterprise value to sales ratio
Latest
92.74
↓ 96% below average
Average (9y)
2143.75
Historical baseline
Range
High:12503.98
Low:-13.01
CAGR
-24.7%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | 92.74 | +613.6% |
| 2023 | 13.00 | -99.8% |
| 2022 | 7322.33 | +132100.1% |
| 2021 | 5.54 | -100.0% |
| 2020 | 12503.98 | +149434.6% |
| 2019 | 8.36 | -97.1% |
| 2018 | 292.43 | +1615.5% |
| 2017 | 17.05 | +231.0% |
| 2016 | -13.01 | -101.1% |
| 2015 | 1195.07 | - |